Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders

E-ISSN： 1873-4286|13|27|2832-2836

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.13, Iss.27, 2007-09, pp. : 2832-2836

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication

Current Pharmaceutical Design, Vol. 14, Iss. 5, 2008-02 ,pp. : 487-495

Bentham Science Publishers

Access to resources Recommend Favorite

Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target

Current Medicinal Chemistry, Vol. 13, Iss. 17, 2006-07 ,pp. : 1971-1978

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-03 ,pp. : 362-368

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

Current Drug Discovery Technologies, Vol. 3, Iss. 1, 2006-03 ,pp. : 83-88

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 962-968

Bentham Science Publishers

Access to resources Recommend Favorite